Randomized Trial Comparing Endocrine Therapy Use Versus Omission in Patients 70 Years and Older With Lower Risk Hormone Receptor-Positive Breast Cancer
Led by Ottawa Hospital Research Institute · Updated on 2026-05-28
500
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the harms and benefits of endocrine therapy in patients aged 70 years or older with lower-risk stage 1 hormone receptor-positive HR breast cancer. The current standard care includes breast-conserving surgery followed by radiotherapy and at least 5 years of endocrine therapy. However, in older patients, the benefit of endocrine therapy may be reduced due to higher risks of death from other causes and the presence of other health conditions that could affect quality of life and functional status.
Participants will be randomly assigned to one of two groups either omission of endocrine therapy or administration of endocrine therapy for at least 5 years. Prior to this, they must have received standard local treatment, including breast-conserving surgery followed by radiotherapy or total mastectomy. The study is multicenter and randomized to assess the balance of benefits and harms associated with endocrine therapy in this older population.
Throughout the study, participants will be followed for up to 5 years. Researchers will assess a hierarchical composite endpoint including overall survival, invasive disease-free survival, metastatic disease-free survival, and quality of life. Additional evaluations will include breast cancer-specific survival, treatment side effects, changes in geriatric health domains, adherence to endocrine therapy, and patient-reported symptoms such as hot flashes and joint pain. Quality of life questionnaires and belief assessments about therapy will be collected at multiple time points to monitor impact and treatment experiences.
CONDITIONS
Brief Title
Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer
Research Team
L
Lisa Vandermeer, MSc
M
Marta Sienkiewicz, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
New invasive estrogen and/or progesterone receptor-positive (ER+ and/or PR+), HER2-negative (HER2-) invasive breast carcinoma diagnosis as per ASCO-CAP guidelines
Primary tumour characteristics must be one of the following: Grade 1 and cm or less on microscope exam, Grade 2 and cm or less, or Grade 3 and cm or less
Treated with standard loco-regional therapy: breast conserving surgery followed by adjuvant radiotherapy OR total mastectomy
Axillary node-negative (cN0 or pN0)
Able to provide oral consent and complete questionnaires in French or English as per study protocol
You will not qualify if you...
Metastatic cancer
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - At least 5 years
Participants receive either endocrine therapy for at least 5 years or no endocrine therapy following their breast conserving surgery and radiotherapy or mastectomy.
Visits at baseline, 26 weeks, and annually up to 5 years for assessments
Follow-up
Duration - Up to 5 years
Participants are monitored for survival, disease recurrence, quality of life, adverse events, and treatment adherence after treatment initiation.
Regular assessments at 26 weeks, 1 year, 2 years, 3 years, 4 years, and 5 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Study Comparing 3D-Printed Biodegradable Breast Implants, Traditional Breast-Conserving Surgery, and Silicone Implant Reconstruction for Breast Cancer Patients
Ultrahypofractionated 5-Session Whole Breast Radiotherapy with Boost versus Standard 15-Session Radiotherapy for Breast Cancer Patients with Unfavorable Characteristics
Phase II Study Comparing 5-Day vs. 9-Day Whole Breast Radiotherapy with Boost in Early-stage Breast Cancer
Evaluating 68Ga-FAPI PETCT for Checking Axillary Lymph Node Status After Neoadjuvant Therapy in Women with Breast Cancer
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey.
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis.
Marie-France Savard, Mark Clemons, Brian Hutton...